1,3,3-Trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine], 97%, 5g

4-Chloro-6-hydrazinyl-2-MethylpyriMidine, 95%, 250mg

1-(2-Amino-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride, 95.0%, 1kg

Phase contrast slide with phasing for PLPH 10x and S40x plan phase objectives

2-methyl-1-(pyridin-4-yl)propan-1-one, 95.0%, 500mg

4-(Dimethylamino)phenyldiphenyl phosphine, 96.0%, 100g

n-Decyltrimethoxysilane, = 97% (GC), 5g

3-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-methylpropanoic acid, 95.0%, 1g

Tris(trimethylsilyl)phosphate, >98.0%(GC), 5g

Ethylenediamine tetraacetic acid, min. 99%, 1 kg, plastic packaging.

6-BROMO-3,4-DIHYDRO-2H-1-BENZOPYRAN-4-OL, 95.0%, 250mg

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-5,5,5-trifluoropentanoic acid, 98%, 1g

S-Benzyl-D-penicillamine, 99.0%, 1g